EUCTR2007-006073-84-BE进行中（未招募）不适用
A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with neovascular age-related maculardegeneration
GlaxoSmithKiline Research and Development0 个研究点目标入组 75 人开始时间: 2008年10月1日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age-related macular degeneration patients diagnosed with subfoveal choroidal neovascularization in the study eye, with all of the following characteristics required:
- •central subfield thickness > 300 microns on investigator-determined OCT (inclusive of subretinal fluid);
- •active subfoveal leakage as determined by investigator-determined fluorescein angiography;
- •minimally classic or occult with no classic CNV lesion;
- •lesion size no greater than 12 disc areas;
- •CNV> 50% of lesion area;
- •< 50% of lesion area with blood;
- •= 25% of lesion area with fibrosis.
- •2. Male or female =50 years of age.
- •3. Best-corrected ETDRS visual acuity in the study eye =23 letters at screening.
- •4. A female subject is eligible to participate if she is of non-childbearing potential defined as either pre-menopausal with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases of postmenopausal status a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140 pmol/L) or value consistent with local laboratory recommended value is confirmatory.
- •5. Subject is willing and able to return for all study visits, and is willing and able to comply with all protocol requirements and procedures.
- •6. Subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. If the subject is unable to read the consent form due to visual impairment then the consent must be read to the subject verbatim by person administering the consent, a family member or legally acceptable representative. If the subject is unable to provide written informed consent due to visual impairment, then written informed consent on behalf of the subject must be provided by a legally acceptable representative.
- •7. QTcF <450msec; or QTcF<480msec in subjects with Bundle Branch Block.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Additional eye disease in the study eye that could compromise best corrected visual acuity (i.e. glaucoma with documented visual field loss, clinically significant diabetic retinopathy, ischemic optic neuropathy, or retinitis pigmentosa).
- •2. CNV in the study eye due to other causes unrelated to age-related macular degeneration.
- •3. The presence of retinal angiomatous proliferation (RAP) in the study eye, as determined by the investigator (confirmation by indocyanine green angiography is not required).
- •4. Geographic atrophy involving the center of the fovea in the study eye.
- •5. Anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation of the fundus for photographs, fluorescein angiography and OCT.
- •6. Vitreous, subretinal or retinal hemorrhage in the study eye that is unrelated to AMD.
- •7. More than one prior photodynamic therapy (PDT) treatment in the study eye.
- •8. PDT treatment in the study eye < 12 weeks prior to dosing.
- •9. Previous treatment in the study eye with ranibizumab (Lucentis) or bevacizumab (Avastin) without resolution of exudation (intraretinal and subretinal fluid as documented by OCT).
- •10. Use of any treatment, either approved or experimental, for AMD in the study eye within 60 days of first dose of investigational product.
- •11. Intraocular surgery in the study eye within 3 months of dosing.
- •12. Aphakia or total absence of the posterior capsule (Yttrium aluminum garnet (YAG) capsulotomy permitted) in the study eye.
- •13. History of vitrectomy in the study eye.
- •14. Use of topical ocular medications in the study eye within 7 days of first dose of investigational product or expected use of topical ocular medications during the treatment period, with the exception of artificial tears (refer to Section 9.1)
- •15. Presence of RPE tear involving the fovea.
- •16. Current use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol).
- •17. Use of systemic steroids (>10 mg prednisone or equivalent/day) within 14 days of first dose.
- •18. An unwillingness to refrain from wearing contact lenses starting from the screening visit, through the follow-up visit
- •19. Medical history or condition:
- •Uncontrolled Diabetes Mellitus, with hemoglobin A1c (HbA1c) > 10%.
- •Myocardial infarction or stroke within 6 months of screening.
- •Active bleeding disorder.
- •Major surgery within 1 month of screening.
- •Hepatic impairment.
- •20. Uncontrolled hypertension, based on criteria provided in Section 7.2.2.
- •Note: Initiation or adjustment of antihypertensive medications is permitted prior to study entry provided the referenced criteria are met.
- •21. ALT or AST above the upper limit of normal or total bilirubin values at or above 1.5 times the upper limit of normal at screening.
- •Note: Laboratory tests outside of the normal range may be repeated at the discretion of the Investigator.
- •22. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result.
- •23. A history of known HIV infection.
- •24. Use of prohibited medications listed in Section 9.2 within the restricted timeframe relative to the first dose of study medication.
- •25. History of drug or alcohol abuse within 6 months of the study.
- •26. History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Moni
研究者
相似试验
进行中（未招募）
不适用
A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with choroidal neovascular age-related macular degeneration. - Pazopanib eye drops in neovascular AMDeovascular age-related macular degenerationMedDRA version: 9.1Level: LLTClassification code 10025409Term: Macular degenerationEUCTR2007-006073-84-ITGlaxoSmithKline Research and Development45
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, INDUCED UNDER INTERNAL BLIND CONDITIONS, TO DETERMINE THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF THE APREPITANT REGIME COMPARED TO AN ONDASETRON REGIME FOR THE PREVENTION OF NAUSEA AND VOMITES INDUCED BY CHEMOTHERAPY, ASSOCIATED WITH HIGH DOSE OF CISPLATINO IN CYCLE 1.PER-057-03MERCK & CO.INC.,
未知
2 期
A Randomized, Double-Blind, Parallel-Group Study of SMP-986 in Patients with Overactive Bladder [Phase 2 Study]Overactive bladderJPRN-jRCT2080221224Dainippon Sumitomo Pharma Co., Ltd.320
进行中（未招募）
不适用
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisRheumatoid ArthritisEUCTR2014-002541-22-GBsanofi-aventis recherche & développement340
进行中（未招募）
1 期
Efficacy and safety of Sarilumab and Adalimumab monotherapy in patients with Rheumatoid ArthritisMedDRA version: 17.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2014-002541-22-ESsanofi-aventis recherche & développement340